SDPA Fall | Live Blog | Product Theater Sponsored by Cipher Pharmaceuticals
Product Theater | “A New Approach to Antiviral Drug Delivery”
Sponsored by: Cipher
Presented by: Daniel Ward, MD
Dr. Daniel Ward discussed “A New Approach to Antiviral Drug Delivery” today during a featured product theater at the SDPA’s 14th Annual Fall Dermatology Conference. Dr. Ward highlighted that up to 85% of the world’s population are seropositive for Herpes Virus 1 (HSV1) with approximately 40% of these patients suffering from recurrent episodes. Sitavig (acyclovir buccal tablets) gives patient’s a new option for the treatment of recurrent herpes labialis due to HSV1. Sitavig is the first and ONLY single dose mucoadhesive buccal tablet that delivers active medication to the area of viral replication. Studies show that Sitavig reduced the viral load in the saliva by 5-fold, increased the time to recurrence with an average of 304 days, and has a very low side effect profile. The tablet is applied to the canine fossa by the patient at the start of their prodromal symptoms (burning, tingling, itching or pain). Dr. Ward stated the patients should press and hold pressure for about 30 seconds, allowing the tablet to adhere to the gum. Tablet needs to stay in for at least 6 hours; however, takes on average 12 – 14 hours to fully dissolve. Dr. Ward finished his presentation by stressing that providers should ensure that patients have access to the medication prior to an outbreak so that they can treat at the time of prodromal symptoms.
Byline: Sarah Patton, PA-C, MSHS
Posted: November 2, 2016